Compositions and foods which contain (1) histidine and (2) vitamin B6 and/or carnosine are useful for treating, improving, and recovering from fatigue.

The present invention relates to a composition comprising compounds sensitive to oxidation and at least one iron-casein protein complex, wherein the complex is a non-micellar iron-casein complex comprising exogenous iron, casein and exogenous orthophosphorus. Such iron-casein complex advantageously does not cause significant oxidation of sensitive compounds such as LC-PUFAs, vitamins and polyphenols.

The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.

The present invention relates to a prebiotic composition comprising a microbially produced oligosaccharide, wherein the oligosaccharide is characterized by being selective for a pre-determined probiotic bacterial strain and also capable of being produced by the pre-determined probiotic bacteria by reverse enzyme action. The present invention also relates to methods of screening a composition suitable for use as a prebiotic and methods for screening of prebiotics for incorporation into synbiotic formulations.

The invention relates to a method for the solid/liquid extraction of an oil or butter, particularly having a high unsaponifiable content, contained in at least one solid vegetable matter or a micro-organism. The method includes at least the following steps: solid/liquid extraction of at least one solid vegetable matter or a micro-organism using a first solvent system comprising a concentration of solvent selected from among fluorinated aromatic solvents, particularly trifluorotoluene (BTF) and hexafluorobenzene (BHF), tert-butyl ethers, particularly 2-ethoxy-2-methylpropane, also known as ethyl-tert-butyl-ether (ETBE), and 2-methoxy-2-methylpropane or methyl-tert-butylether (MTBE), solvents comprising at least one silicon atom, particularly hexamethyldisiloxane (HMDS) and tetramethylsilane (TMS), methyl-tetrahydrofuran (MeTHF), and mixtures thereof, representing at least 50 vol.-% in relation to the total volume of the solvent system; and, optionally, recovery of a fraction comprising the oil or butter, particularly unsaponifiable enriched. The invention also relates to an unsaponifiable fraction, oil or butter obtained using this method and to compositions containing said oil or fraction.

Disclosed are 1,25-dihydroxy-24,24-difluoro-2-methylene-19-nor-vitamin D analogs and their pharmaceutical uses. These new vitamin D analogs are 19-nor-vitamin D analogs having two fluorine atom substitutions at the 24 position (C-24) in the side chain and optionally having a 2-methylene substituent.

Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

The present invention disclosed a formulation in the form of self-emulsifying drug delivery formulation for improved delivery of tocotrienols comprising a fat-soluble compound, at least one emulsifier, and an oil carrier. The formulation shows an improved bioavailability of tocotrienols.

Cysteine compositions comprising less than about 400 g/L of aluminum. For example, solutions of cysteine comprising a pharmaceutically acceptable solvent, cysteine, and less than about 145 g/L of aluminum, wherein the solution is devoid of visible particulate matter. Cysteine compositions described herein may be suitable for injection. For example, disclosed cysteine solutions may be provided intravenously to meet amino acid nutritional requirement in individuals receiving total parenteral nutrition. Also provided are processes for preparing cysteine compositions, and methods for providing cysteine to individuals in need thereof.

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.